K
Kyverna Therapeutics, Inc. (KYTX)
NMS – Real vaqt narxi. Valyuta: USD
8.44
+0.24 (2.93%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
8.44
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 6:02 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
8.44
+0.24 (2.93%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
8.44
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 6:02 PM EDT
Kyverna Therapeutics, Inc., keyingi bosqichdagi biofarmatsevtika kompaniyasi, autoimmün kasalliklarga chalingan bemorlar uchun hujayra terapiyasini ishlab chiqishga qaratilgan. Uning yetakchi mahsulot nomzodi KYV-101 bo'lib, qattiq tana sindromi, miyasteniya gravis va autoimmün kasalliklarni davolash uchun CD19 ga qarshi yo'naltirilgan autolog CAR T-hujayrali mahsulot nomzodidir. Kompaniya shuningdek, to'liq qondan tez ishlab chiqariladigan autolog CD19 CAR T-hujayrali mahsulot nomzodi KYV-102 va allogen CD19 CAR T-hujayrali mahsulot nomzodi KYV-201ni ishlab chiqmoqda. U Intellia Therapeutics, Inc. bilan allogen CD19 ga qarshi yo'naltirilgan CAR hujayrali terapiyasi mahsulotini tadqiq qilish va ishlab chiqish bo'yicha litsenziya va hamkorlik shartnomasiga ega. Kompaniya ilgari BAIT Therapeutics, Inc. nomi bilan tanilgan va 2019-yil oktabr oyida Kyverna Therapeutics, Inc. nomini olgan. Kyverna Therapeutics, Inc. 2018-yilda ro'yxatga olingan va uning shtab-kvartirasi Kaliforniyaning Emervil shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Marc Grasso M.D. | Strategic Advisor |
| Dr. Naji H. Gehchan M.B.A., M.D. | Chief Medical & Development Officer |
| Dr. Tom Van Blarcom Ph.D. | Senior VP & Head of Research |
| Mr. Gregory Martini | Chief Financial Officer |
| Mr. Mayo Pujols | Chief Technology Officer |
| Mr. Warner Biddle | CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-02 | 8-K | kytx-20260527.htm |
| 2026-05-18 | 8-K | kytx-20260514.htm |
| 2026-05-12 | 8-K | kytx-20260512.htm |
| 2026-05-12 | 10-Q | kytx-20260331.htm |
| 2026-05-04 | 8-K | kytx-20260415.htm |
| 2026-04-22 | 8-K | d100817d8k.htm |
| 2026-04-20 | 8-K | kytx-20260420.htm |
| 2026-04-13 | DEFA14A | kytx_-_defa14a_proxy_not.htm |
| 2026-04-13 | DEF 14A | kytx-20260410.htm |
| 2026-04-13 | ARS | kytx_2025_asr_annual_rep.pdf |
| Ms. Christi L. Shaw | Executive Chairperson |
| Ms. Jessica Serra | Head of Investor Relations |